Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Crizotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 11/20 | 1.00 |
| ▸ | ALK known ✓ | Q9UM73 | 7/20 | 1.00 |
| ▸ | ROS1 known ✓ | P08922 | 2/20 | 1.00 |
| ▸ | MST1R known ✓ | Q04912 | 2/20 | 1.00 |
| ▸ | NPM1 known ✓ | P06748 | 1/20 | 1.00 |
| ▸ | EML4 known ✓ | Q9HC35 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 7/20 | 1.00 |
| ▸ | MAP4K3 | Q8IVH8 | 7/20 | 1.00 |
| ▸ | JAK3 | P52333 | 4/20 | 1.00 |
| ▸ | JAK1 | P23458 | 3/20 | 1.00 |
| ▸ | TYK2 | P29597 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 2/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 2/20 | 1.00 |
| ▸ | INSR | P06213 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Crizotinib SCHEMBL93829 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL14811801 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL94020 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29622387 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL28844303 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL28844302 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29351506 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL30129754 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29831273 | 0.99 | MET (0.98) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL1827232 | 0.95 | MET (0.91) | METALKJAK2MAP4K3JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731199-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING COLORECTAL CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024263813-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING COLORECTAL CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240342153-A1 | TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION USING (S)-CRIZOTINIB | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2024-10-17 | — | — | US | disclosed |
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-11590233-B2 | Porphyrin compounds and compositions useful for treating cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2023015197-A1 | TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION USING (S)-CRIZOTINIB | VANDA PHARMACEUTICALS INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| CN-109922834-B | Porphyrin compounds and compositions for the treatment of cancer | 良药治疗公司 | 2022-09-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342153-A1 | TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION USING (S)-CRIZOTINIB | ACE2, TMPRSS2, ABL1 | MET 48/4885ALK 4/4885ROS1 33/4885 |
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | KIT, HCCS, PPIF | MET 643/4885ALK 3057/4885ROS1 1770/4885 |
| US-11590233-B2 | Porphyrin compounds and compositions useful for treating cancer | KIT, HCCS, PPIF | MET 643/4885ALK 3057/4885ROS1 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.